Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.2
2.8
Journals
Genes
Special Issues
Role of Non-coding RNA in Blood Diseases
share announcement

Role of Non-coding RNA in Blood Diseases

A special issue of Genes (ISSN 2073-4425). This special issue belongs to the section "Human Genomics and Genetic Diseases".

Deadline for manuscript submissions: closed (15 February 2023) | Viewed by 5212

Special Issue Editor

Prof. Dr. Duonan Yu

E-Mail Website
Guest Editor
Institute of Translational Medicine, Yangzhou University School of Medicine, Yangzhou University, Yangzhou, China
Interests: blood disorders; blood neoplasm; non-coding RNA; miRNA; LncRNA; RNA therapies

Special Issue Information

Dear Colleagues,

I would like to invite you to participate in this Special Issue on the “Role of Non-Coding RNA in Blood Diseases”.

Approximately 90% of the human genomic DNA is transcribed to produce RNAs. However, only 2% of these RNAs come from protein‐coding genes. In other words, the vast majority of these RNAs are non-coding RNAs. Since Croce’s group first described the role of microRNAs in human blood malignancy in 2002, growing evidence has demonstrated that aberrant expression of non-coding RNAs is linked to blood diseases. This evidence indicates the potential value of non-coding RNAs as biomarkers or therapeutic targets for disease diagnosis and treatment. Over 30 RNA-based therapeutics including miRNA mimics and antimiRs are approved by the FDA and/or the European Medicines Agency or in phase II or III clinical trials. Although promising, the road to the cure of blood disorders by RNA therapies remains long.

This Special Issue aims to host research and review papers on our understanding of the role of non-coding RNAs in blood diseases. Cutting-edge results from animal models or patients with blood disorders will be considered for publication.

Prof. Dr. Duonan Yu
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Genes is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • blood disorders
  • blood neoplasm
  • non-coding RNA
  • miRNA
  • LncRNA
  • RNA therapies

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

13 pages, 18471 KiB  
Article
Crosstalk between miR-144/451 and Nrf2 during Recovery from Acute Hemolytic Anemia
by Lei Yang, Sheng He, Ling Ling, Fangfang Wang, Lei Xu, Lei Fang, Fan Wu, Shuting Zhou, Fan Yang, Hongwei Wei and Duonan Yu
Genes 2023, 14(5), 1011; https://doi.org/10.3390/genes14051011 - 29 Apr 2023
Cited by 1 | Viewed by 1778
Abstract
miR-144/451 and nuclear factor (erythroid-derived 2)-like 2 (Nrf2) regulate two antioxidative systems that have been identified to maintain redox homeostasis in erythroid cells by removing excess reactive oxygen species (ROS). Whether these two genes coordinate to affect ROS scavenging and the [...] Read more.
miR-144/451 and nuclear factor (erythroid-derived 2)-like 2 (Nrf2) regulate two antioxidative systems that have been identified to maintain redox homeostasis in erythroid cells by removing excess reactive oxygen species (ROS). Whether these two genes coordinate to affect ROS scavenging and the anemic phenotype, or which gene is more important for recovery from acute anemia, has not been explored. To address these questions, we crossed miR-144/451 knockout (KO) and Nrf2 KO mice and examined the phenotype change in the animals as well as the ROS levels in erythroid cells either at baseline or under stress condition. Several discoveries were made in this study. First, Nrf2/miR-144/451 double-KO mice unexpectedly exhibit similar anemic phenotypes as miR-144/451 single-KO mice during stable erythropoiesis, although compound mutations of miR-144/451 and Nrf2 lead to higher ROS levels in erythrocytes than single gene mutations. Second, Nrf2/miR-144/451 double-mutant mice exhibit more dramatic reticulocytosis than miR-144/451 or Nrf2 single-KO mice during days 3 to 7 after inducing acute hemolytic anemia using phenylhydrazine (PHZ), indicating a synergistic effect of miR-144/451 and Nrf2 on PHZ-induced stress erythropoiesis. However, the coordination does not persist during the whole recovery stage of PHZ-induced anemia; instead, Nrf2/miR-144/451 double-KO mice follow a recovery pattern similar to miR-144/451 single-KO mice during the remaining period of erythropoiesis. Third, the complete recovery from PHZ-induced acute anemia in miR-144/451 KO mice takes longer than in Nrf2 KO mice. Our findings demonstrate that complicated crosstalk between miR-144/451 and Nrf2 does exist and the crosstalk of these two antioxidant systems is development-stage-dependent. Our findings also demonstrate that miRNA deficiency could result in a more profound defect of erythropoiesis than dysfunctional transcription factors. Full article
(This article belongs to the Special Issue Role of Non-coding RNA in Blood Diseases)
►▼ Show Figures

Figure 1

Review

Jump to: Research

20 pages, 1070 KiB  
Review
The Promising Role of Non-Coding RNAs as Biomarkers and Therapeutic Targets for Leukemia
by Mohammad H. Ghazimoradi, Naeim Karimpour-Fard and Sadegh Babashah
Genes 2023, 14(1), 131; https://doi.org/10.3390/genes14010131 - 3 Jan 2023
Cited by 9 | Viewed by 2922
Abstract
Early-stage leukemia identification is crucial for effective disease management and leads to an improvement in the survival of leukemia patients. Approaches based on cutting-edge biomarkers with excellent accuracy in body liquids provide patients with the possibility of early diagnosis with high sensitivity and [...] Read more.
Early-stage leukemia identification is crucial for effective disease management and leads to an improvement in the survival of leukemia patients. Approaches based on cutting-edge biomarkers with excellent accuracy in body liquids provide patients with the possibility of early diagnosis with high sensitivity and specificity. Non-coding RNAs have recently received a great deal of interest as possible biomarkers in leukemia due to their participation in crucial oncogenic processes such as proliferation, differentiation, invasion, apoptosis, and their availability in body fluids. Recent studies have revealed a strong correlation between leukemia and the deregulated non-coding RNAs. On this basis, these RNAs are also great therapeutic targets. Based on these advantages, we tried to review the role of non-coding RNAs in leukemia. Here, the significance of several non-coding RNA types in leukemia is highlighted, and their potential roles as diagnostic, prognostic, and therapeutic targets are covered. Full article
(This article belongs to the Special Issue Role of Non-coding RNA in Blood Diseases)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop